Sarah Balladares
Toledo, OHNPI 1356859896
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $197,024 of the $230,720 with a category attached, or 85.4%. Galderma Laboratories, L.p. accounts for 96.6% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $111,260 and has fallen 75.0% since, to $27,803 in 2025.
Across 343 payments — averaging $672.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$223K
- Merz North America, Inc.$6K
- AbbVie$2K
- Revance Therapeutics, Inc.$100
- Heron Therapeutics, Inc.$13
What the payments were for
- Consulting fees$6900%
- Speaking & faculty fees$197,02485%
- Travel & lodging$25,24211%
- Food & beverage$7,7643%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 287 | $222,841 |
| Merz North America, Inc. | 41 | $5,953 |
| AbbVie(2 entities) | 13 | $1,814 |
| Revance Therapeutics, Inc. | 1 | $100 |
| Heron Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$5,025
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.